novavax covid vaccine

Order byBest matchMost fresh

Novavax Soars

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

· 1d · on MSN

Novavax Soars After Covid Vaccine Secures Full FDA Approval

AARP · 1d

Third COVID Vaccine Gets Approved for Adults 65 and Over

· 17h

US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant

The U.S. Senate plans to vote this week to bar California's landmark plan to end the sale of gasoline-only vehicles by 2035 that has been adopted by 11 other states, Majority Leader John Thune said on...

· 10h

F.D.A. Poised to Restrict Access to Covid Vaccines

· 11h

New Trump Vaccine Policy Limits Access To COVID Shots

· 13h

New FDA rule could delay Covid vaccine rollout for healthy adults and kids

NBC News’ Berkeley Lovelace Jr. explains how this will impact healthy adults.

· 18h

FDA sets new COVID booster guidelines for healthy adults under 65

· 20h

FDA to limit future Covid-19 shots to older people and those at risk of serious infection

18hon MSN

Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at low risk," the agency said in an article published by The New England Journal of Medicine, authored by FDA Commissioner Dr. Martin Makary and his new top vaccines official, Dr. Vinay Prasad.

11hon MSN

New Trump vaccine policy limits access to COVID shots

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy

Novavax (NasdaqGS:NVAX) Reports Q1 2025 Financial Turnaround

Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration agreement with Takeda offers increased flexibility in vaccine development,